JPH11510044A - タンパク質p5、脳損傷用血清マーカー - Google Patents
タンパク質p5、脳損傷用血清マーカーInfo
- Publication number
- JPH11510044A JPH11510044A JP9506499A JP50649997A JPH11510044A JP H11510044 A JPH11510044 A JP H11510044A JP 9506499 A JP9506499 A JP 9506499A JP 50649997 A JP50649997 A JP 50649997A JP H11510044 A JPH11510044 A JP H11510044A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- protein
- brain
- proteins
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710132807 Protein P5 Proteins 0.000 title claims abstract description 14
- 210000002966 serum Anatomy 0.000 title claims abstract description 14
- 239000003550 marker Substances 0.000 title abstract 2
- 208000029028 brain injury Diseases 0.000 title description 3
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004556 brain Anatomy 0.000 claims abstract description 19
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 13
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 13
- 238000003556 assay Methods 0.000 claims abstract description 12
- 230000006378 damage Effects 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 22
- 238000003018 immunoassay Methods 0.000 claims description 12
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 5
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims 2
- 238000007818 agglutination assay Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 239000000499 gel Substances 0.000 description 12
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000008001 CAPS buffer Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 4
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 102000009265 Cerebrospinal Fluid Proteins Human genes 0.000 description 3
- 108010073496 Cerebrospinal Fluid Proteins Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 208000031134 Meningeal disease Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 102000018361 Contactin Human genes 0.000 description 1
- 108060003955 Contactin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.脳又は血液−脳関門の損傷を、血液又は血清試料から診断することにおける タンパク質P5又はその抗体の使用。 2.a)脳又は血液−脳関門に損傷を受けていると思われる患者の血液又は血清 のアッセイを行い、 b)P5の存在又はその量を測定し、 c)P5の存在又はその量を脳又は血液−関門に対する損傷の発生と関連づけ ることを含む脳又は血液−脳関門に対する損傷の検出方法。 3.イムノアッセイである第2項に記載の方法。 4.イムノアッセイがELISAである第3項に記載の方法。 5.イムノアッセイが凝集アッセイである第3項に記載の方法。 6.アッセイが、血液又は血清試料の一次元又は二次元ゲル電気泳動を行い、そ れによってP5を分離し、P5をそれの抗体を用いてイムノブロッティングし、 このイムノブロットを検出することを含む第3項に記載の方法。 7.イムノアッセイがイムノポリメラーゼ連鎖反応アッセイである第3項に記載 の方法。 8.特異的にP5と結合し、髄液又は血液のその他のタンパク質と交差反応しな いモノクローナル抗体。 9.特異的にP5と結合し、髄液又は血液のその他のタンパク質と交差反応しな いモノクローナル抗体を生産するハイブリドーマ細胞株。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US139195P | 1995-07-24 | 1995-07-24 | |
US60/001,391 | 1995-07-24 | ||
PCT/IB1996/000739 WO1997004315A1 (en) | 1995-07-24 | 1996-07-19 | Protein p5, a serum marker for brain damage |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11510044A true JPH11510044A (ja) | 1999-09-07 |
Family
ID=21695806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9506499A Pending JPH11510044A (ja) | 1995-07-24 | 1996-07-19 | タンパク質p5、脳損傷用血清マーカー |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0842432A1 (ja) |
JP (1) | JPH11510044A (ja) |
KR (1) | KR19990035921A (ja) |
AU (1) | AU6316496A (ja) |
CA (1) | CA2227882A1 (ja) |
WO (1) | WO1997004315A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001040789A1 (fr) * | 1999-12-02 | 2001-06-07 | Hymo Corporation | Gels de polyacrylamide premoules pour l'electrophorese, procede de production de ces derniers et procede d'electrophorese dans lequel on utilise ces gels |
EP2955517A1 (de) * | 2014-06-10 | 2015-12-16 | Siemens Healthcare Diagnostics Products GmbH | Verfahren zur Stabilisierung von Körperflüssigkeitsproben durch die Zugabe von Detergenz |
-
1996
- 1996-07-19 CA CA002227882A patent/CA2227882A1/en not_active Abandoned
- 1996-07-19 KR KR1019980700582A patent/KR19990035921A/ko not_active Application Discontinuation
- 1996-07-19 JP JP9506499A patent/JPH11510044A/ja active Pending
- 1996-07-19 AU AU63164/96A patent/AU6316496A/en not_active Abandoned
- 1996-07-19 EP EP96922194A patent/EP0842432A1/en not_active Withdrawn
- 1996-07-19 WO PCT/IB1996/000739 patent/WO1997004315A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0842432A1 (en) | 1998-05-20 |
AU6316496A (en) | 1997-02-18 |
CA2227882A1 (en) | 1997-02-06 |
WO1997004315A1 (en) | 1997-02-06 |
KR19990035921A (ko) | 1999-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0756708B1 (en) | Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation | |
EP0699306B1 (en) | Assay for cardiac troponin i | |
KR101067817B1 (ko) | Aimp1 폴리펩티드에 대한 항체를 포함하는 관절염 진단용 조성물 | |
EP0201187B1 (en) | Determination of glycated (glycosylated) hemoglobin in blood | |
US20110065205A1 (en) | Method for determining prognosis of acute central nervous system disorder | |
US20090023165A1 (en) | Methods for Early Diagnosis of Kidney Disease | |
JPH11510596A (ja) | ヒト急性期血清アミロイドaタンパク質、組換えタンパク質、特異的抗体の定量的測定法 | |
US5246835A (en) | Method of diagnosing renal diseases | |
KR100689995B1 (ko) | 알돌라제를 포함하는 망막혈관 질환 진단용 조성물 및 그진단방법 | |
US5284750A (en) | Serum proteins related to autoimmune disease | |
KR19990067153A (ko) | 프로스타글란딘 디 신타아제에 특이적인 단일클론항체 | |
JPH11510044A (ja) | タンパク質p5、脳損傷用血清マーカー | |
US7736864B2 (en) | Detection of inflammation | |
JP3015121B2 (ja) | 非A1c糖化ヘモグロビンに対するモノクローナル抗体 | |
US4590168A (en) | Protein immunoassaying and purification | |
WO2010038831A1 (ja) | 細胞増殖を伴う糖尿病合併症の検査のための方法、組成物およびキット | |
JPH04252954A (ja) | タンパクの測定方法、試薬及びキット | |
US5242801A (en) | Diagnosing malignant hyperthermia susceptibility by detection of abnormal proteolytic enzyme digestion fragments of the ryanodine receptor | |
US20050032117A1 (en) | Method for assessment of cystic lung fibrosis | |
WO2004009640A1 (ja) | 抗菌性ペプチドに対する抗体及びその利用 | |
JP2848705B2 (ja) | ヒト肺サーフアクタントアポ蛋白dに対するモノクローナル抗体およびその用途 | |
JP2007121310A (ja) | 自己免疫疾患診断剤 | |
WO1993009142A1 (en) | Acute phase proteins for detection and prognosis of infection and tissue damage | |
JPH04252955A (ja) | 蛋白質の測定方法、試薬及びキット | |
JP2007254428A (ja) | 天然で未変性のcdtに対する抗体、抗体の製造方法、ハイブリドーマ、及び免疫測定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090114 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090114 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100114 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110114 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120114 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130114 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130114 Year of fee payment: 13 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |